Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

Abstract: A system and method to connect a cryocooler (refrigerator) to a superconducting magnet or cooled object allows for replacement without the need to break the cryostat vacuum or the need to warm up the superconducting magnet or other cooled object. A pneumatic or other type of actuator establishes a thermo-mechanical coupling. The mechanical closing forces are directed perpendicular (cross-axially) to the cryocooler axis and are not applied to the thin wall cryocooler body or to the thin cryostat walls or to the cooled object or to its shield. It is also possible that some of the compressive force be transferred to the cryocooler body. In that case, the extensions are designed so that the forces transferred to the cryocooler thermal stages do not exceed allowable stresses in the cryocooler stage.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: A novel thermal coupler apparatus and method to couple a cryocooler or another cooling device to a superconducting magnet or cooled object allows for replacement without a need to break the cryostat vacuum or to warm up the superconducting magnet or other cooled object. A method uses a pneumatic actuator for coupling, and a retractable mechanical actuator for uncoupling. Mechanical closing forces are balanced between the intermediate temperature and low temperature cooling surfaces and do not transfer to the cooled object. The pneumatic actuator provides permanent control under mechanical closing forces in the thermal coupling.

Abstract: A novel thermal coupler apparatus and method to couple a cryocooler or another cooling device to a superconducting magnet or cooled object allows for replacement without a need to break the cryostat vacuum or to warm up the superconducting magnet or other cooled object. A method uses a pneumatic actuator for coupling, and a retractable mechanical actuator for uncoupling. Mechanical closing forces are balanced between the intermediate temperature and low temperature cooling surfaces and do not transfer to the cooled object. The pneumatic actuator provides permanent control under mechanical closing forces in the thermal coupling.

Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

Abstract: A system and method to connect a cryocooler (refrigerator) to a superconducting magnet or cooled object allows for replacement without the need to break the cryostat vacuum or the need to warm up the superconducting magnet or other cooled object. A pneumatic or other type of actuator establishes a thermo-mechanical coupling. The mechanical closing forces are directed perpendicular (cross-axially) to the cryocooler axis and are not applied to the thin wall cryocooler body or to the thin cryostat walls or to the cooled object or to its shield. It is also possible that some of the compressive force be transferred to the cryocooler body. In that case, the extensions are designed so that the forces transferred to the cryocooler thermal stages do not exceed allowable stresses in the cryocooler stage.

Abstract: The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or APRIL-related disorders.